Industry News

Cockerell Named Medical Director of Sensus Healthcare

Clay Cockerell has been named Medical Director of Sensus Healthcare, a provider of noninvasive skin cancer and keloid scar treatment technologies. Dr. Cockerell will lead the company’s medical advisory board.
"I am excited to be involved with Sensus and for the opportunity to see the ongoing development of dermatologic radiotherapy. This is an excellent technique that provides a very good supplement in select patients to the excellent dermatologic surgical techniques, including Mohs Surgery, that we routinely employ," said Dr. Cockerell.

Crutchfield Honored as Most Influential Leader of 2013

Dermatologist Charles E. Crutchfield III, MD, of Crutchfield Dermatology has been selected by for inclusion on its 2013 list of most influential African-American history and industry leaders.
Former honorees include Michelle Obama, Beyonce, Adrian Peterson, Tyler Perry, Neil deGrasse Tyson (Physicist and Astronomer), Susan Rice, LeVar Burton, Robert Griffin III, Gabby Douglas, Maya Rudolph, Keith Ellison, Tyra Banks, Rihanna, Quvenzhane Wallis, Ken Williams (General manager, Chicago White Sox), Wynton Marsalis, Charles Bolden, LeBron James, and Oprah Winfrey.

Medicis and Mentor Join Forces With Physician Loyalty Program

Medicis, a division of Valeant Pharmaceuticals, that develops facial injectables and professional skin care, is collaborating with Mentor Worldwide, a market leader in breast aesthetics, to create a combined physician loyalty program that includes several of their non-reimbursed products. The new M2VP (Medicis-Mentor Valued Partner) program extends the offerings of Medicis' recently-launched MVP program to include the MENTOR line of breast implant products for a five-year term and is for the U.S., subject to any geographical expansion that may be agreed upon by the parties.

30% of consumers considering cosmetic procedures

Nearly 30% of consumers say they are considering a cosmetic procedure with dermatologists named as the greatest influence for their decision, according to a new survey by the American Society for Dermatologic Surgery (ASDS,
The ASDS Consumer Survey on Cosmetic Dermatologic Procedures asked more than 6,300 consumers in a blind online survey to share their opinions on cosmetic treatments in general and rate 10 specific procedures—ranging from botulinum toxin injections and body sculpting to laser hair removal.

Cynosure Completes Acquisition of Palomar

Aesthetic device manufacturer Cynosure has completed of its acquisition of Palomar Medical Technologies. Cynosure purchased Palomar in a cash and stock transaction valued at approximately $287 million. In the transaction, Cynosure issued approximately six million shares and paid approximately $146 million in cash contributed by both Cynosure and Palomar. The closing of the transaction follows approvals by Cynosure stockholders and Palomar stockholders at separate meetings on June 24, 2013.

Connecticut State Law Targets Non-Physician-Run Medspas

Connecticut State Law Targets Non-Physician-Run Medspas

Medical spas in Connecticut that offer cosmetic medical procedures must have an acting medical director who is a state-licensed physician. Bill SB-1067, which goes into effect on October 1, 2013, was passed by the state’s legislature on June 5, 2013. It states that any medical spa that offers procedures defined under the state’s sales tax laws as “cosmetic medical procedures” employ or contract with a medical director. An MD, PA, APRN or RN may perform the procedures. If a PA, APRN or RN is performing the treatment, he or she must be acting under a physician’s supervision and control.

Prollenium Medical Launches Dermal Filler Manufacturing Facility in Canada

Prollenium Medical Technologies, a manufacturer of medical devices and dermal fillers used in cosmetic and plastic surgery treatments worldwide, has opened a new facility, just north of Toronto, Canada. Its flagship product lines include Revanesse, Phiderma and RheoVital.
The company reports that the new facility is ISO 13485 registered as well as Health Canada and CE approved. It employs a fully automated process in a clean room environment with sterilization, packaging and quality control taking place in-house. The site also houses the company's marketing, sales and R&D teams.

Phase II Results for New Minocycline Topical

Phase II Results for New Minocycline Topical

Foamix, a clinical stage specialty pharmaceutical company, has completed Phase II clinical trials of its Minocycline Foam 4%, a first topical minocycline product that can be used for the treatment of acne, rosacea and skin infections. The double blind, dose ranging, placebo controlled study followed 150 patients with moderate to severe acne. Patients were randomized into three equal groups of 50 patients, who received placebo, or one of two Minocycline Foams--1% or 4%.

Quinnova to Co-Promote Refissa

Suneva Medical, a privately-held aesthetics company, has selected Quinnova Pharmaceuticals, a premier provider of therapeutic skin and wound products in the United States, to co-promote ReFissa. ReFissa is the only FDA approved 0.05% tretinoin emollient cream indicated for the treatment of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin.